These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma.
    Author: Mounier N, Briere J, Gisselbrecht C, Reyes F, Gaulard P, Coiffier B, Groupe d'Etude des Lymphomes de l'Adulte.
    Journal: Haematologica; 2006 May; 91(5):715-6. PubMed ID: 16670080.
    Abstract:
    Rituximab plus CHOP (R-CHOP) has been proven to increase overall survival in aggressive bcl-2-positive lymphoma patients. Using competing risk analysis, we studied the long-term impact of this treatment in patients from a GELA trial: R-CHOP prevented from progression or relapse in both bcl-2-positive and bcl-2-negative patients without increasing the risk of death in complete remission.
    [Abstract] [Full Text] [Related] [New Search]